South San Francisco, Calif.-based Global Blood Therapeutics Inc. said it appointed David Johnson as its chief commercial officer, effective March 12.
Johnson will create and lead the biotechnology company's commercial operations and will be responsible for building and leading sales, marketing, business analytics and market access.
Global Blood Therapeutics is a clinical-stage biopharmaceutical company focused on finding treatments for blood-based disorders. The company is developing voxelotor, previously called GBT440, as a potential disease-modifying therapy for sickle cell disease, an inherited blood disorder.
Johnson joins the company from Gilead Sciences Inc., where he was vice president of sales and marketing for the company's liver disease business unit.
